LAUSR

Lemborexant: First Approval

Sign Up to like & get
recommendations!
0 Published in 2020 at "Drugs"

DOI: 10.1007/s40265-020-01276-1

Abstract: Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of… read more here.

Keywords: lemborexant first; first approval; treatment; approval ... See more keywords